Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-26 | GEORGE L. SING, 66, has been a Director of the Company since January 1988. Since 1998, he has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. From January 2004 to April 2015, Mr. Sing served as Chief Executive Officer of Stemnion, Inc., a biomedical company in the regenerative medicine field. Mr. Sing's extensive healthcare and financial expertise as a healthcare venture capital investor and biomedical company chief executive officer, his executive leadership experience, and his substantial knowledge of the Company led the board to conclude that Mr. Sing should serve as a director. |
| 2017-04-25 | Since 1998, Mr. Sing has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. ... Compensation of Directors: George L. Sing 2,104,085. |
| 2018-04-23 | GEORGE L. SING Since 1998, Mr. Sing has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. From January 2004 to April 2015, Mr. Sing served as Chief Executive Officer of Stemnion, Inc. (currently known as Noveome Biotherapeutics, Inc.), a biomedical company in the regenerative medicine field. Mr. Sing's extensive healthcare and financial expertise as a healthcare venture capital investor and biomedical company chief executive officer, his executive leadership experience, and his substantial knowledge of the Company led to the board's decision to nominate Mr. Sing for reelection to the board. Board and Committee Membership: Board of Directors, Audit Committee (Chairman), Compensation Committee. Compensation of Directors table shows $1,232,211 option awards and $85,000 fees earned in cash totaling $1,317,211. |
| 2021-04-23 | Since 1998, Mr. Sing has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. In addition, since 2016, Mr. Sing has served as Chief Executive Officer of GanD, Inc., a biomedical drug development company. Mr. Sing's extensive healthcare and financial expertise as a healthcare venture capital investor and biomedical company chief executive officer, his executive leadership experience, and his substantial knowledge of the Company led to the board's decision to nominate Mr. Sing for reelection to the board. Board and Committee Membership—2020 Attendance: Board of Directors: 11/11 Audit Committee (Chairman): 11/11 Compensation Committee: 13/13 Prior Voting Results—2018: For: 64.0% Against: 36.0% Regeneron Securities Beneficially Owned as of April 13, 2021: Common Stock: 59,022 Options: 45,028 RSUs: 750 |
| 2022-04-21 | George L. Sing Director since: 1988 Age: 72 Independent Board and Committee Membership–2021 Attendance Board of Directors: 9/9 Audit Committee (Chair): 10/10 Compensation Committee: 15/15 Director Compensation Table: George L. Sing Total: 723,594 |
| 2024-04-25 | George L. Sing - Director since 1988, Age 74, Independent. CEO of GanD, Inc. Board and Committee Membership—2023 Attendance: Audit Committee (Chair), Compensation Committee. Compensation: $724,987. |
Data sourced from SEC filings. Last updated: 2025-12-06